Literature DB >> 12069960

Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.

Stéphane Carryn1, Françoise Van Bambeke, Marie-Paule Mingeot-Leclercq, Paul M Tulkens.   

Abstract

The activities of ampicillin, meropenem, azithromycin, gentamicin, ciprofloxacin, and moxifloxacin against intracellular hemolysin-positive Listeria monocytogenes were measured in human THP-1 macrophages and were compared with the extracellular activities observed in broth. All extracellular concentrations were adjusted to explore ranges that are clinically achievable in human serum upon conventional therapy. In broth, ampicillin, meropenem, and azithromycin were only bacteriostatic, whereas gentamicin, ciprofloxacin, and moxifloxacin were strongly bactericidal in a concentration-dependent manner. In cells, ampicillin, meropenem, azithromycin, and ciprofloxacin were slightly bactericidal (0.3- to 0.8-log CFU reductions), moxifloxacin was strongly bactericidal (2.1-log CFU reduction), and gentamicin was virtually inactive. The difference in the efficacies of moxifloxacin and ciprofloxacin in cells did not result from a difference in levels of accumulation in cells (6.96 +/- 1.05 versus 7.75 +/- 1.03) and was only partially explainable by the difference in the MICs (0.58 +/- 0.04 versus 1.40 +/- 0.17 mg/liter). Further analysis showed that intracellular moxifloxacin expressed only approximately 1/7 of the activity demonstrated against extracellular bacteria and ciprofloxacin expressed only 1/15 of the activity demonstrated against extracellular bacteria. Gentamicin did not increase the intracellular activities of the other antibiotics tested. The data suggest (i) that moxifloxacin could be of potential interest for eradication of the intracellular forms of L. monocytogenes, (ii) that the cellular accumulation of an antibiotic is not the only determinant of its intracellular activity (for fluoroquinolones, it is actually a self-defeating process as far as activity is concerned), and (iii) that pharmacodynamics (activity-to-concentration relationships) need to be considered for the establishment of efficacy against intracellular bacteria, just as they are for the establishment of efficacy against extracellular infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069960      PMCID: PMC127291          DOI: 10.1128/AAC.46.7.2095-2103.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts.

Authors:  P Tulkens; A Trouet
Journal:  Biochem Pharmacol       Date:  1978-02-15       Impact factor: 5.858

3.  Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Authors:  J T Sullivan; M Woodruff; J Lettieri; V Agarwal; G J Krol; P T Leese; S Watson; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  Fluorometric analysis of ampicillin in biological fluids.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

5.  Enzymatic method for rapid and sensitive determination of beta-lactam antibiotics.

Authors:  J M Frère; D Klein; J M Ghuysen
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

6.  Autoradiographic evidence for the impermeability of mouse peritoneal macrophages to tritiated streptomycin.

Authors:  P F Bonventre; R Hayes; J Imhoff
Journal:  J Bacteriol       Date:  1967-01       Impact factor: 3.490

7.  The ketolide antibiotic HMR 3647, a candidate substance for the treatment of systemic and intracerebral infections with Listeria monocytogenes.

Authors:  T Nichterlein; M Kretschmar; H Hof
Journal:  Zentralbl Bakteriol       Date:  1999-04

8.  Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model.

Authors:  Delphine Paillard; Jean Grellet; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 9.  Treatment of listeriosis.

Authors:  M E Temple; M C Nahata
Journal:  Ann Pharmacother       Date:  2000-05       Impact factor: 3.154

10.  Membrane flow during pinocytosis. A stereologic analysis.

Authors:  R M Steinman; S E Brodie; Z A Cohn
Journal:  J Cell Biol       Date:  1976-03       Impact factor: 10.539

View more
  38 in total

1.  Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.

Authors:  Anne Sandberg; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Diarmaid Hughes; Christof von Eiff; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Authors:  Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

4.  Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Authors:  Radha K Shandil; Ramesh Jayaram; Parvinder Kaur; Sheshagiri Gaonkar; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

6.  Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.

Authors:  S Grayo; O Join-Lambert; M C Desroches; A Le Monnier
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

7.  Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

8.  Meropenem therapy failure in Listeria monocytogenes infection.

Authors:  S Stepanović; G Lazarević; M Jesić; R Kos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-13       Impact factor: 3.267

9.  Rapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosis.

Authors:  Solène Grayo; Marie-Catherine Lott-Desroches; Olivier Dussurget; Renaud Respaud; Arnaud Fontanet; Olivier Join-Lambert; Eric Singlas; Alban Le Monnier
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

10.  Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.

Authors:  Ann Lismond; Paul M Tulkens; Marie-Paule Mingeot-Leclercq; Patrice Courvalin; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.